JACK V. TALLEY
Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors raising in aggregate in excess of $100 million. Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs. Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer. Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process. Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
GABRIEL NUSSBAUM, MD, PhD
Director of Scientific Affairs
Dr. Nussbaum trained and was US board-certified in internal medicine after completing an MD/PhD at the Albert Einstein College of Medicine. He performed post-doctoral studies at the Weizmann Institute of Science, an internationally known research center in Israel. He continues to be actively involved in the investigation of inflammation and autoimmunity. In addition , Dr. Nussbaum has research experience with botanicals, specifically cannabis. Dr. Nussbaum has numerous publications in leading scientific journals.
Mr. Kraus commenced as COO of Izun in 2013. For the 12 years prior to this, Les served as Chief Financial Officer of Retail Apparel Group Pty Ltd (RAG), the largest menswear retailer in Australia. During his time at RAG, Les managed two sale processes to private equity firms. He is a qualified Chartered Accountant in Australia and has over 30 years of operational and financial experience within the clothing industry, covering both retail and wholesale businesses.
SHIMON LECHT, PhD,R.Ph.
R&D Team Manager
Dr. Lecht recently joined the CannRx team to lead the R&D. He is an experienced multidisciplinary basic and translational researcher. Dr. Lecht brings along a valuable experience in pre-clinical project management from early discovery to clinical trials. Prior to joining CannRx, Dr. Lecht took a leading part in several botanical drug development projects, provided regulatory services to bio-tech start-up companies towards first interaction with FDA and co-founded a pharmaceutical consulting company.
Dr. Lecht completed a post-doctoral training in Regenerative Medicine (Temple University, PA), holds a PhD and an MSc in Pharmacology from the Hebrew University in Jerusalem and is a licensed pharmacist in Israel.
Dr. Lecht published numerous peer-reviewed publications and presented at dozens of international meetings and conferences.
Dr. Nussbaum has numerous publications in leading scientific journals.
Mr. Kraus is a qualified Chartered Accountant in Australia and has over 30 years of operational and financial experience
Dr. Cohen completed two post-doctoral fellowships, the first in cell adhesion and smoke-induced pulmonary disease at the Weizmann Institute of Science, and the second in Rheumatoid Arthritis
Some facts about us!
Dr. Cohen is a research scientist and project leader at CannRx Technology, Inc. Dr. Cohen is a research immunologist with a background in the genetic engineering of crop plants. Following a Master's degree in agricultural biotechnology from the Hebrew University, he earned a PhD in cellular immunology from the Hebrew University with a focus on multiple sclerosis. Dr. Cohen completed two post-doctoral fellowships, the first in cell adhesion and smoke-induced pulmonary disease at the Weizmann Institute of Science, and the second in Rheumatoid Arthritis at the Hebrew University-Hadassah Faculty of Medicine. Dr. Cohen has published his research in high-ranking academic journals.
SHMUEL COHEN, PhD
CannRx Technology Inc.
One Rockefeller Plaza, 11th Floor
New York, NY 10020
© 2016 Copyright by CannRx Technology Inc. All Rights Reserved.